4-chlorophenylbiguanide profile

4-Chlorophenylbiguanide is a synthetic compound with a complex structure. It has been studied for its potential as a drug candidate due to its ability to interact with various biological targets. Research has focused on its antimicrobial properties, particularly against bacteria and fungi. Its mechanism of action involves disrupting the synthesis of essential components in microbial cells, leading to cell death. However, there are limited studies on its pharmacokinetic and toxicological profiles, and its clinical application is still under investigation. The compound has also been studied for its potential in other areas such as anti-inflammatory and anticancer therapies.'

ID Source	ID
PubMed CID	19933
CHEMBL ID	840
SCHEMBL ID	305068
SCHEMBL ID	19038548
MeSH ID	M0085762

Synonym
bdbm50053595
4-chloro-phenyl biguanide
61uq98597t ,
nsc 220325
1-(4-chlorophenyl)biguanide
imidodicarbonimidic diamide, n-(4-chlorophenyl)-
einecs 226-155-6
unii-61uq98597t
ai3-52174
biguanide, 1-(p-chorophenyl)-
5304-59-6
nsc-220325
nsc220325
1-carbamimidoyl-3-(4-chlorophenyl)guanidine
n-(4-chlorophenyl)imidodicarbonimidic diamide
STK105980
MAYBRIDGE1_007004
MAYBRIDGE4_003042
MAYBRIDGE1_007100
NCGC00176274-01
4-chlorophenylbiguanide
HMS1529K06
CHEMBL840 ,
BRD-K18824214-001-01-8
HMS561K16
AKOS002224800
2-(4-chlorophenyl)-1-(diaminomethylidene)guanidine
p-chlorophenylbiguanide
BBL003340
1-carbamimidamido-n-(4-chlorophenyl)methanimidamide
AB00443650-03
n-(4-chlorophenyl)imidodicarbonimidic diamide hydrochloride
SCHEMBL305068
p-chlorophenyldiguanide
([(4-chloroanilino)(imino)methyl]amino)methanimidamide
HTYFFCPFVMJTKM-UHFFFAOYSA-N
1-(p-chlorophenyl)diguanide
n1-(p-chlorophenyl)biguanide
(4-chlorophenyl)biguanide
(p-chlorophenyl)biguanide
DTXSID10201086
SCHEMBL19038548
CCG-248174
VS-01306
Q27263381
NCGC00341330-01
CS-0322974
PD129496
1-{[{[amino(imino)methyl]amino}(imino)methyl]amino}-4-chlorobenzene

Excerpt	Reference	Relevance
" The pharmacokinetic properties of proguanil were similar during and after pregnancy."	( Single dose pharmacokinetics of proguanil and its metabolites in pregnancy. Moody, RR; Nosten, F; Taylor, RB; ter Kuile, F; Wangboonskul, J; White, NJ, 1993)	0.29

Excerpt	Relevance	Reference
" The currently recommended dosage regimen appears to be appropriate for extensive metabolisers of proguanil."	( The multiple dose pharmacokinetics of proguanil. Breckenridge, AM; Edwards, G; Helsby, NA; Ward, SA, 1993)	0.29

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
5-hydroxytryptamine receptor 3E	Homo sapiens (human)	Ki	0.2033	0.0010	0.8835	9.9000	AID6339; AID6343
5-hydroxytryptamine receptor 3B	Homo sapiens (human)	Ki	0.2033	0.0010	0.8711	9.9000	AID6339; AID6343
Integrin beta-3	Homo sapiens (human)	IC50 (µMol)	148.6000	0.0001	0.6323	10.0000	AID276738
Integrin alpha-V	Homo sapiens (human)	IC50 (µMol)	148.6000	0.0001	0.6256	10.0000	AID276738
5-hydroxytryptamine receptor 3A	Homo sapiens (human)	Ki	0.2033	0.0000	0.7411	9.9000	AID6339; AID6343
5-hydroxytryptamine receptor 3D	Homo sapiens (human)	Ki	0.2033	0.0010	0.8835	9.9000	AID6339; AID6343
5-hydroxytryptamine receptor 3C	Homo sapiens (human)	Ki	0.2033	0.0010	0.8835	9.9000	AID6339; AID6343
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Trace amine-associated receptor 1	Mus musculus (house mouse)	EC50 (µMol)	2.1000	0.0020	0.6970	5.4000	AID1426078
Trace amine-associated receptor 1	Homo sapiens (human)	EC50 (µMol)	10.0000	0.0150	1.4143	7.1900	AID1426080
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
monoatomic ion transmembrane transport	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
excitatory postsynaptic potential	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
inorganic cation transmembrane transport	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
regulation of membrane potential	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
monoatomic ion transmembrane transport	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
excitatory postsynaptic potential	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
inorganic cation transmembrane transport	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
regulation of membrane potential	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
negative regulation of low-density lipoprotein receptor activity	Integrin beta-3	Homo sapiens (human)
positive regulation of protein phosphorylation	Integrin beta-3	Homo sapiens (human)
positive regulation of endothelial cell proliferation	Integrin beta-3	Homo sapiens (human)
positive regulation of cell-matrix adhesion	Integrin beta-3	Homo sapiens (human)
cell-substrate junction assembly	Integrin beta-3	Homo sapiens (human)
cell adhesion	Integrin beta-3	Homo sapiens (human)
cell-matrix adhesion	Integrin beta-3	Homo sapiens (human)
integrin-mediated signaling pathway	Integrin beta-3	Homo sapiens (human)
embryo implantation	Integrin beta-3	Homo sapiens (human)
blood coagulation	Integrin beta-3	Homo sapiens (human)
positive regulation of endothelial cell migration	Integrin beta-3	Homo sapiens (human)
positive regulation of gene expression	Integrin beta-3	Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiation	Integrin beta-3	Homo sapiens (human)
positive regulation of fibroblast migration	Integrin beta-3	Homo sapiens (human)
negative regulation of lipid storage	Integrin beta-3	Homo sapiens (human)
response to activity	Integrin beta-3	Homo sapiens (human)
smooth muscle cell migration	Integrin beta-3	Homo sapiens (human)
positive regulation of smooth muscle cell migration	Integrin beta-3	Homo sapiens (human)
platelet activation	Integrin beta-3	Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathway	Integrin beta-3	Homo sapiens (human)
cell-substrate adhesion	Integrin beta-3	Homo sapiens (human)
activation of protein kinase activity	Integrin beta-3	Homo sapiens (human)
negative regulation of lipid transport	Integrin beta-3	Homo sapiens (human)
regulation of protein localization	Integrin beta-3	Homo sapiens (human)
regulation of actin cytoskeleton organization	Integrin beta-3	Homo sapiens (human)
cell adhesion mediated by integrin	Integrin beta-3	Homo sapiens (human)
positive regulation of cell adhesion mediated by integrin	Integrin beta-3	Homo sapiens (human)
positive regulation of osteoblast proliferation	Integrin beta-3	Homo sapiens (human)
heterotypic cell-cell adhesion	Integrin beta-3	Homo sapiens (human)
substrate adhesion-dependent cell spreading	Integrin beta-3	Homo sapiens (human)
tube development	Integrin beta-3	Homo sapiens (human)
wound healing, spreading of epidermal cells	Integrin beta-3	Homo sapiens (human)
cellular response to platelet-derived growth factor stimulus	Integrin beta-3	Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathway	Integrin beta-3	Homo sapiens (human)
wound healing	Integrin beta-3	Homo sapiens (human)
apoptotic cell clearance	Integrin beta-3	Homo sapiens (human)
regulation of bone resorption	Integrin beta-3	Homo sapiens (human)
positive regulation of angiogenesis	Integrin beta-3	Homo sapiens (human)
positive regulation of bone resorption	Integrin beta-3	Homo sapiens (human)
symbiont entry into host cell	Integrin beta-3	Homo sapiens (human)
platelet-derived growth factor receptor signaling pathway	Integrin beta-3	Homo sapiens (human)
positive regulation of fibroblast proliferation	Integrin beta-3	Homo sapiens (human)
mesodermal cell differentiation	Integrin beta-3	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Integrin beta-3	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Integrin beta-3	Homo sapiens (human)
negative regulation of lipoprotein metabolic process	Integrin beta-3	Homo sapiens (human)
negative chemotaxis	Integrin beta-3	Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosol	Integrin beta-3	Homo sapiens (human)
regulation of serotonin uptake	Integrin beta-3	Homo sapiens (human)
angiogenesis involved in wound healing	Integrin beta-3	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Integrin beta-3	Homo sapiens (human)
platelet aggregation	Integrin beta-3	Homo sapiens (human)
cellular response to mechanical stimulus	Integrin beta-3	Homo sapiens (human)
cellular response to xenobiotic stimulus	Integrin beta-3	Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferation	Integrin beta-3	Homo sapiens (human)
blood coagulation, fibrin clot formation	Integrin beta-3	Homo sapiens (human)
maintenance of postsynaptic specialization structure	Integrin beta-3	Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalization	Integrin beta-3	Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trapping	Integrin beta-3	Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreading	Integrin beta-3	Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathway	Integrin beta-3	Homo sapiens (human)
regulation of trophoblast cell migration	Integrin beta-3	Homo sapiens (human)
regulation of extracellular matrix organization	Integrin beta-3	Homo sapiens (human)
cellular response to insulin-like growth factor stimulus	Integrin beta-3	Homo sapiens (human)
negative regulation of endothelial cell apoptotic process	Integrin beta-3	Homo sapiens (human)
positive regulation of T cell migration	Integrin beta-3	Homo sapiens (human)
cell migration	Integrin beta-3	Homo sapiens (human)
negative regulation of low-density lipoprotein receptor activity	Integrin alpha-V	Homo sapiens (human)
angiogenesis	Integrin alpha-V	Homo sapiens (human)
vasculogenesis	Integrin alpha-V	Homo sapiens (human)
cell adhesion	Integrin alpha-V	Homo sapiens (human)
cell-matrix adhesion	Integrin alpha-V	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Integrin alpha-V	Homo sapiens (human)
integrin-mediated signaling pathway	Integrin alpha-V	Homo sapiens (human)
positive regulation of cell population proliferation	Integrin alpha-V	Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiation	Integrin alpha-V	Homo sapiens (human)
negative regulation of lipid storage	Integrin alpha-V	Homo sapiens (human)
cell migration	Integrin alpha-V	Homo sapiens (human)
positive regulation of cell migration	Integrin alpha-V	Homo sapiens (human)
cell-substrate adhesion	Integrin alpha-V	Homo sapiens (human)
negative regulation of lipid transport	Integrin alpha-V	Homo sapiens (human)
cell adhesion mediated by integrin	Integrin alpha-V	Homo sapiens (human)
positive regulation of osteoblast proliferation	Integrin alpha-V	Homo sapiens (human)
heterotypic cell-cell adhesion	Integrin alpha-V	Homo sapiens (human)
substrate adhesion-dependent cell spreading	Integrin alpha-V	Homo sapiens (human)
wound healing, spreading of epidermal cells	Integrin alpha-V	Homo sapiens (human)
endodermal cell differentiation	Integrin alpha-V	Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathway	Integrin alpha-V	Homo sapiens (human)
apoptotic cell clearance	Integrin alpha-V	Homo sapiens (human)
positive regulation of cell adhesion	Integrin alpha-V	Homo sapiens (human)
symbiont entry into host cell	Integrin alpha-V	Homo sapiens (human)
negative regulation of lipoprotein metabolic process	Integrin alpha-V	Homo sapiens (human)
regulation of phagocytosis	Integrin alpha-V	Homo sapiens (human)
negative chemotaxis	Integrin alpha-V	Homo sapiens (human)
positive regulation of small GTPase mediated signal transduction	Integrin alpha-V	Homo sapiens (human)
ERK1 and ERK2 cascade	Integrin alpha-V	Homo sapiens (human)
calcium ion transmembrane transport	Integrin alpha-V	Homo sapiens (human)
transforming growth factor beta production	Integrin alpha-V	Homo sapiens (human)
entry into host cell by a symbiont-containing vacuole	Integrin alpha-V	Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligand	Integrin alpha-V	Homo sapiens (human)
positive regulation of intracellular signal transduction	Integrin alpha-V	Homo sapiens (human)
negative regulation of entry of bacterium into host cell	Integrin alpha-V	Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway	Integrin alpha-V	Homo sapiens (human)
cell-cell adhesion	Integrin alpha-V	Homo sapiens (human)
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
monoatomic ion transmembrane transport	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
excitatory postsynaptic potential	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
inorganic cation transmembrane transport	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
regulation of presynaptic membrane potential	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
regulation of membrane potential	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
monoatomic ion transmembrane transport	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
excitatory postsynaptic potential	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
inorganic cation transmembrane transport	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
regulation of membrane potential	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
monoatomic ion transmembrane transport	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
excitatory postsynaptic potential	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
inorganic cation transmembrane transport	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
regulation of membrane potential	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Trace amine-associated receptor 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
serotonin-gated monoatomic cation channel activity	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
serotonin-gated monoatomic cation channel activity	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
fibroblast growth factor binding	Integrin beta-3	Homo sapiens (human)
C-X3-C chemokine binding	Integrin beta-3	Homo sapiens (human)
insulin-like growth factor I binding	Integrin beta-3	Homo sapiens (human)
neuregulin binding	Integrin beta-3	Homo sapiens (human)
virus receptor activity	Integrin beta-3	Homo sapiens (human)
fibronectin binding	Integrin beta-3	Homo sapiens (human)
protease binding	Integrin beta-3	Homo sapiens (human)
protein disulfide isomerase activity	Integrin beta-3	Homo sapiens (human)
protein kinase C binding	Integrin beta-3	Homo sapiens (human)
platelet-derived growth factor receptor binding	Integrin beta-3	Homo sapiens (human)
integrin binding	Integrin beta-3	Homo sapiens (human)
protein binding	Integrin beta-3	Homo sapiens (human)
coreceptor activity	Integrin beta-3	Homo sapiens (human)
enzyme binding	Integrin beta-3	Homo sapiens (human)
identical protein binding	Integrin beta-3	Homo sapiens (human)
vascular endothelial growth factor receptor 2 binding	Integrin beta-3	Homo sapiens (human)
metal ion binding	Integrin beta-3	Homo sapiens (human)
cell adhesion molecule binding	Integrin beta-3	Homo sapiens (human)
extracellular matrix binding	Integrin beta-3	Homo sapiens (human)
fibrinogen binding	Integrin beta-3	Homo sapiens (human)
opsonin binding	Integrin alpha-V	Homo sapiens (human)
protein kinase C binding	Integrin alpha-V	Homo sapiens (human)
fibroblast growth factor binding	Integrin alpha-V	Homo sapiens (human)
C-X3-C chemokine binding	Integrin alpha-V	Homo sapiens (human)
insulin-like growth factor I binding	Integrin alpha-V	Homo sapiens (human)
neuregulin binding	Integrin alpha-V	Homo sapiens (human)
virus receptor activity	Integrin alpha-V	Homo sapiens (human)
fibronectin binding	Integrin alpha-V	Homo sapiens (human)
protease binding	Integrin alpha-V	Homo sapiens (human)
integrin binding	Integrin alpha-V	Homo sapiens (human)
voltage-gated calcium channel activity	Integrin alpha-V	Homo sapiens (human)
protein binding	Integrin alpha-V	Homo sapiens (human)
coreceptor activity	Integrin alpha-V	Homo sapiens (human)
metal ion binding	Integrin alpha-V	Homo sapiens (human)
transforming growth factor beta binding	Integrin alpha-V	Homo sapiens (human)
extracellular matrix binding	Integrin alpha-V	Homo sapiens (human)
extracellular matrix protein binding	Integrin alpha-V	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
serotonin-gated monoatomic cation channel activity	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
identical protein binding	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
serotonin-gated monoatomic cation channel activity	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
serotonin-gated monoatomic cation channel activity	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
G protein-coupled receptor activity	Trace amine-associated receptor 1	Homo sapiens (human)
trace-amine receptor activity	Trace amine-associated receptor 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
postsynaptic membrane	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
serotonin-activated cation-selective channel complex	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
neuron projection	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
transmembrane transporter complex	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
postsynaptic membrane	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
serotonin-activated cation-selective channel complex	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
cell surface	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
transmembrane transporter complex	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
neuron projection	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
glutamatergic synapse	Integrin beta-3	Homo sapiens (human)
nucleus	Integrin beta-3	Homo sapiens (human)
nucleoplasm	Integrin beta-3	Homo sapiens (human)
plasma membrane	Integrin beta-3	Homo sapiens (human)
cell-cell junction	Integrin beta-3	Homo sapiens (human)
focal adhesion	Integrin beta-3	Homo sapiens (human)
external side of plasma membrane	Integrin beta-3	Homo sapiens (human)
cell surface	Integrin beta-3	Homo sapiens (human)
apical plasma membrane	Integrin beta-3	Homo sapiens (human)
platelet alpha granule membrane	Integrin beta-3	Homo sapiens (human)
lamellipodium membrane	Integrin beta-3	Homo sapiens (human)
filopodium membrane	Integrin beta-3	Homo sapiens (human)
microvillus membrane	Integrin beta-3	Homo sapiens (human)
ruffle membrane	Integrin beta-3	Homo sapiens (human)
integrin alphav-beta3 complex	Integrin beta-3	Homo sapiens (human)
melanosome	Integrin beta-3	Homo sapiens (human)
synapse	Integrin beta-3	Homo sapiens (human)
postsynaptic membrane	Integrin beta-3	Homo sapiens (human)
extracellular exosome	Integrin beta-3	Homo sapiens (human)
integrin alphaIIb-beta3 complex	Integrin beta-3	Homo sapiens (human)
glycinergic synapse	Integrin beta-3	Homo sapiens (human)
integrin complex	Integrin beta-3	Homo sapiens (human)
protein-containing complex	Integrin beta-3	Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complex	Integrin beta-3	Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complex	Integrin beta-3	Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complex	Integrin beta-3	Homo sapiens (human)
receptor complex	Integrin beta-3	Homo sapiens (human)
alphav-beta3 integrin-vitronectin complex	Integrin beta-3	Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complex	Integrin beta-3	Homo sapiens (human)
focal adhesion	Integrin beta-3	Homo sapiens (human)
cell surface	Integrin beta-3	Homo sapiens (human)
synapse	Integrin beta-3	Homo sapiens (human)
cytosol	Integrin alpha-V	Homo sapiens (human)
plasma membrane	Integrin alpha-V	Homo sapiens (human)
focal adhesion	Integrin alpha-V	Homo sapiens (human)
cell surface	Integrin alpha-V	Homo sapiens (human)
membrane	Integrin alpha-V	Homo sapiens (human)
lamellipodium membrane	Integrin alpha-V	Homo sapiens (human)
filopodium membrane	Integrin alpha-V	Homo sapiens (human)
microvillus membrane	Integrin alpha-V	Homo sapiens (human)
ruffle membrane	Integrin alpha-V	Homo sapiens (human)
integrin alphav-beta1 complex	Integrin alpha-V	Homo sapiens (human)
integrin alphav-beta3 complex	Integrin alpha-V	Homo sapiens (human)
integrin alphav-beta5 complex	Integrin alpha-V	Homo sapiens (human)
integrin alphav-beta6 complex	Integrin alpha-V	Homo sapiens (human)
integrin alphav-beta8 complex	Integrin alpha-V	Homo sapiens (human)
specific granule membrane	Integrin alpha-V	Homo sapiens (human)
phagocytic vesicle	Integrin alpha-V	Homo sapiens (human)
extracellular exosome	Integrin alpha-V	Homo sapiens (human)
integrin complex	Integrin alpha-V	Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complex	Integrin alpha-V	Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complex	Integrin alpha-V	Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complex	Integrin alpha-V	Homo sapiens (human)
external side of plasma membrane	Integrin alpha-V	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
cleavage furrow	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
postsynaptic membrane	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
serotonin-activated cation-selective channel complex	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
transmembrane transporter complex	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
neuron projection	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
postsynaptic membrane	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
serotonin-activated cation-selective channel complex	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
transmembrane transporter complex	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
neuron projection	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
postsynaptic membrane	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
serotonin-activated cation-selective channel complex	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
transmembrane transporter complex	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
neuron projection	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
plasma membrane	Trace amine-associated receptor 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (33)

Assay ID	Title	Year	Journal	Article
AID1426082	Selectivity ratio of EC50 for human TAAR1 expressed in HEK293 cells to EC50 for mouse TAAR1 expressed in HEK293 cells	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Novel biguanide-based derivatives scouted as TAAR1 agonists: Synthesis, biological evaluation, ADME prediction and molecular docking studies.
AID1485250	Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009(H1N1) infected in MDCK cells assessed as host cell viability measured after 3 to 6 days post infection by MTS assay	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1485247	Antiviral activity against Influenza B virus B/Ned/537/05 infected in MDCK cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by formazan-based colorimetric assay	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1426079	Agonist activity at human TAAR1 expressed in HEK293 cells assessed as cAMP accumulation at 10 uM after 20 mins by BRET assay relative to beta-PEA	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Novel biguanide-based derivatives scouted as TAAR1 agonists: Synthesis, biological evaluation, ADME prediction and molecular docking studies.
AID1485246	Antiviral activity against Influenza B virus B/Ned/537/05 infected in MDCK cells assessed as host cell viability measured after 3 to 6 days post infection by MTS assay	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1485249	Antiviral activity against Influenza A virus A/Ned/378/05(H1N1) infected in MDCK cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by formazan-based colorimetric assay	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID276738	Inhibition of integrin alphavbeta3 mediated cell adhesion of human M21 cells to vitronectin	2006	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 16, Issue:22	Discovery of small molecule inhibitors of integrin alphavbeta3 through structure-based virtual screening.
AID1485243	Antiviral activity against para influenza 3 virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1485242	Antiviral activity against vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1485238	Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1426077	Agonist activity at mouse TAAR1 expressed in HEK293 cells assessed as cAMP accumulation at 10 uM after 20 mins by BRET assay relative to beta-PEA	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Novel biguanide-based derivatives scouted as TAAR1 agonists: Synthesis, biological evaluation, ADME prediction and molecular docking studies.
AID1426080	Agonist activity at human TAAR1 expressed in HEK293 cells assessed as cAMP accumulation after 20 mins by BRET assay	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Novel biguanide-based derivatives scouted as TAAR1 agonists: Synthesis, biological evaluation, ADME prediction and molecular docking studies.
AID1485240	Cytotoxicity against human HeLa cells assessed as alterations in cell morphology measured after 5 to 6 days post infection by microscopic analysis	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1485251	Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009(H1N1) infected in MDCK cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by formazan-based colorimetric assay	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1485231	Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1485235	Antiviral activity against Yellow fever virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1485239	Antiviral activity against Reovirus 1 infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1485236	Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1485255	Cytotoxicity against African green monkey Vero cells assessed as alterations in cell morphology measured after 5 to 6 days post infection by microscopic analysis	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1426081	Agonist activity at mouse TAAR5 expressed in HEK293 cells assessed as cAMP accumulation after 20 mins by BRET assay	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Novel biguanide-based derivatives scouted as TAAR1 agonists: Synthesis, biological evaluation, ADME prediction and molecular docking studies.
AID1485244	Cytotoxicity against dog MDCK cells assessed as alterations in normal cell morphology measured after 5 to 6 days post infection by microscopic analysis	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1485241	Antiviral activity against coxsackie B4 virus infected in human HeLa cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID6343	Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	Structure-activity relationships for the binding of arylpiperazines and arylbiguanides at 5-HT3 serotonin receptors.
AID1485245	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability measured after 5 to 6 days by MTS assay	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1426078	Agonist activity at mouse TAAR1 expressed in HEK293 cells assessed as cAMP accumulation after 20 mins by BRET assay	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Novel biguanide-based derivatives scouted as TAAR1 agonists: Synthesis, biological evaluation, ADME prediction and molecular docking studies.
AID6339	Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.	2001	Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12	The binding of arylguanidines at 5-HT(3) serotonin receptors: a structure-affinity investigation.
AID1485248	Antiviral activity against Influenza A virus A/Ned/378/05(H1N1) infected in MDCK cells assessed as host cell viability measured after 3 to 6 days post infection by MTS assay	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1485237	Antiviral activity against Coxsackie B4 virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	4 (14.81)	18.7374
1990's	11 (40.74)	18.2507
2000's	5 (18.52)	29.6817
2010's	6 (22.22)	24.3611
2020's	1 (3.70)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	2 (7.41%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	25 (92.59%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
8-hydroxy-2-(di-n-propylamino)tetralin 8-Hydroxy-2-(di-n-propylamino)tetralin: A serotonin 1A-receptor agonist that is used experimentally to test the effects of serotonin.. 8-OH-DPAT : A tetralin substituted at positions 1 and 7 by hydroxy and dipropylamino groups respectively	1.99	1	0	phenols; tertiary amino compound; tetralins	serotonergic antagonist
1-(1-naphthyl)piperazine 1-(1-naphthyl)piperazine: serotonin agonist; structure given in first source	1.99	1	0	N-arylpiperazine
1-(2-methoxyphenyl)piperazine 1-(2-methoxyphenyl)piperazine: RN given refers to parent cpd	1.99	1	0	piperazines
1-(3-chlorophenyl)biguanide 1-(3-chlorophenyl)biguanide: RN given refers to parent cp; a 5-HT3 receptor agonist	2.94	4	0	biguanides; monochlorobenzenes
1-(3-chlorophenyl)piperazine 1-(3-chlorophenyl)piperazine: supposed metabolite of TRAZODONE; RN given refers to parent cpd; structure. 1-(3-chlorophenyl)piperazine : A N-arylpiperazine that is piperazine carrying a 3-chlorophenyl substituent at position 1. It is a metabolite of the antidepressant drug trazodone.	1.99	1	0	monochlorobenzenes; N-arylpiperazine	drug metabolite; environmental contaminant; serotonergic agonist; xenobiotic
amantadine amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source	2.15	1	0	adamantanes; primary aliphatic amine	analgesic; antiparkinson drug; antiviral drug; dopaminergic agent; NMDA receptor antagonist; non-narcotic analgesic
chloroquine Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.	1.96	1	0	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
mephenytoin Mephenytoin: An anticonvulsant effective in tonic-clonic epilepsy (EPILEPSY, TONIC-CLONIC). It may cause blood dyscrasias.. mephenytoin : An imidazolidine-2,4-dione (hydantoin) in which the imidazolidine nucleus carries a methyl group at N-3 and has ethyl and phenyl substituents at C-5. An anticonvulsant, it is no longer available in the USA or the UK but is still studied largely because of its interesting hydroxylation polymorphism.	4.29	4	1	imidazolidine-2,4-dione	anticonvulsant
1-(3-trifluoromethylphenyl)piperazine 1-(3-trifluoromethylphenyl)piperazine: acts as serotonin agonist; structure. 1-(3-(trifluoromethyl)phenyl)piperazine : A N-arylpiperazine that is piperazine substituted by a 3-(trifluoromethyl)phenyl group at position 1. A serotonergic agonist used as a recreational drug.	1.99	1	0	(trifluoromethyl)benzenes; N-arylpiperazine	environmental contaminant; psychotropic drug; serotonergic agonist; xenobiotic
phenyl biguanide phenyl biguanide: RN given refers to parent cpd. phenyl biguanide : A member of the class of biguanides that is biguanide in which one of the terminal nitrogen atoms is substituted by a phenyl group.	2.94	4	0	guanidines	central nervous system drug
pyrimethamine Maloprim: contains above 2 cpds	2.72	3	0	aminopyrimidine; monochlorobenzenes	antimalarial; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
quipazine Quipazine: A pharmacologic congener of serotonin that contracts smooth muscle and has actions similar to those of tricyclic antidepressants. It has been proposed as an oxytocic.	2.4	2	0	piperazines; pyridines
n-methylquipazine N-methylquipazine: structure in first source. N-methylquipazine : An aminoquinoline that consists of quinoline in which the hydrogen at position 2 is substituted by a 4-methylpiperazin-1-yl group. A 5-HT3 agonist. Has almost the same affinity for 5-HT3 sites as quipazine but unlike the latter, does not bind to 5-HT1B sites.	1.99	1	0	aminoquinoline; N-alkylpiperazine; N-arylpiperazine	serotonergic agonist
rimantadine Rimantadine: An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.	2.15	1	0	alkylamine
trimethoprim Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.	2.55	2	0	aminopyrimidine; methoxybenzenes	antibacterial drug; diuretic; drug allergen; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; environmental contaminant; xenobiotic
biguanides Biguanides: Derivatives of biguanide (the structure formula HN(C(NH)NH2)2) that are primarily used as oral HYPOGLYCEMIC AGENTS for the treatment of DIABETES MELLITUS, TYPE 2 and PREDIABETES.. biguanides : A class of oral hypoglycemic drugs used for diabetes mellitus or prediabetes treatment. They have a structure based on the 2-carbamimidoylguanidine skeleton.	6.13	17	2	guanidines
phenylpiperazine phenylpiperazine: RN given refers to parent cpd	1.99	1	0
cycloguanil cycloguanil: the active metabolite of proguanil; antifolate drug; structure in first source. cycloguanil : A triazine in which a 1,6-dihydro-1,3,5-triazine ring is substituted at N-1 by a 4-chlorophenyl group, at C-2 and -4 by amino groups and at C-6 by gem-dimethyl groups. A dihydrofolate reductase inhibitor, it is a metabolite of the antimalarial drug proguanil.	6.19	18	2	triazines	antifolate; antiinfective agent; antimalarial; antiparasitic agent; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
phenylguanidine phenylguanidine: RN given refers to parent cpd	2.4	2	0
4,6-diamino-2,2-dimethyl-1,2-dihydro-1-phenyl-s-triazine 4,6-diamino-2,2-dimethyl-1,2-dihydro-1-phenyl-s-triazine: structure in first source	2.15	1	0
ribavirin Rebetron: Rebetron is tradename	2.15	1	0	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
zanamivir Zanamivir: A guanido-neuraminic acid that is used to inhibit NEURAMINIDASE.	2.15	1	0	guanidines	antiviral agent; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor
4-phenylpiperidine [no description available]	1.99	1	0
2,4-diamino-5,6-dihydro-6,6-dimethyl-5-(4'-methoxyphenyl)-s-triazine 2,4-diamino-5,6-dihydro-6,6-dimethyl-5-(4'-methoxyphenyl)-s-triazine: RN given refers to parent cpd; structure given in first source	2.15	1	0
1-(4-chlorophenyl)piperazine 1-(4-chlorophenyl)piperazine: increases serotonin & decreases 5-hydroxyindoleacetic acid concentration in rat brain 6 hours after administration; RN given refers to parent cpd	1.99	1	0
methotrexate [no description available]	2.15	1	0	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
1-(4-methoxyphenyl)piperazine 1-(4-methoxyphenyl)piperazine: a designer drug; structure in first source	1.99	1	0
mycophenolic acid Mycophenolic Acid: Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION.. mycophenolate : A monocarboxylic acid anion resulting from the removal of a proton from the carboxy group of mycophenolic acid.. mycophenolic acid : A member of the class of 2-benzofurans that is 2-benzofuran-1(3H)-one which is substituted at positions 4, 5, 6, and 7 by methyl, methoxy, (2E)-5-carboxy-3-methylpent-2-en-1-yl, and hydroxy groups, respectively. It is an antibiotic produced by Penicillium brevi-compactum, P. stoloniferum, P. echinulatum and related species. An immunosuppressant, it is widely used (partiularly as its sodium salt and as the 2-(morpholin-4-yl)ethyl ester prodrug, mycophenolate mofetil) to prevent tissue rejection following organ transplants and for the treatment of certain autoimmune diseases.	2.15	1	0	2-benzofurans; gamma-lactone; monocarboxylic acid; phenols	anticoronaviral agent; antimicrobial agent; antineoplastic agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; environmental contaminant; immunosuppressive agent; mycotoxin; Penicillium metabolite; xenobiotic
2-(4-chlorophenyl)guanidine [no description available]	2.4	2	0	organochlorine compound
fluvoxamine Fluvoxamine: A selective serotonin reuptake inhibitor that is used in the treatment of DEPRESSION and a variety of ANXIETY DISORDERS.. fluvoxamine : An oxime O-ether that is benzene substituted by a (1E)-N-(2-aminoethoxy)-5-methoxypentanimidoyl group at position 1 and a trifluoromethyl group at position 4. It is a selective serotonin reuptake inhibitor that is used for the treatment of obsessive-compulsive disorder.	3.38	1	1	(trifluoromethyl)benzenes; 5-methoxyvalerophenone O-(2-aminoethyl)oxime	antidepressant; anxiolytic drug; serotonin uptake inhibitor
proguanil Proguanil: A biguanide compound which metabolizes in the body to form cycloguanil, an anti-malaria agent.. proguanil : A biguanide compound which has isopropyl and p-chlorophenyl substituents on the terminal N atoms. A prophylactic antimalarial drug, it works by inhibiting the enzyme dihydrofolate reductase, which is involved in the reproduction of the malaria parasites Plasmodium falciparum and P. vivax within the red blood cells.	6.19	18	2	biguanides; monochlorobenzenes	antimalarial; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
cyclic(arg-gly-asp-d-phe-val) [no description available]	2.03	1	0
3-iodothyronamine 3-iodothyronamine: a thyroid hormone derivative that may be involved in a fast response signaling pathway; structure in first source	2.15	1	0	aromatic ether
m-chlorophenylguanidine [no description available]	2.4	2	0

Condition	Relationship Strength	Studies
Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.	1.99	1
Encephalitis, Polio [description not available]	2.06	1
Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)	2.06	1
Plasmodium falciparum Malaria [description not available]	2.1	1
Malaria, Falciparum Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.	2.1	1
Anemia, Fanconi [description not available]	2.13	1
Fanconi Anemia Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)	2.13	1
Complications, Parasitic Pregnancy [description not available]	1.98	1
Infections, Plasmodium [description not available]	1.98	1
Malaria A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.	1.98	1
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	1.98	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.69	3
Aggression Behavior which may be manifested by destructive and attacking action which is verbal or physical, by covert attitudes of hostility or by obstructionism.	1.99	1

4-chlorophenylbiguanide

Cross-References

Synonyms (49)

Research Excerpts

Pharmacokinetics

Dosage Studied

Protein Targets (10)

Inhibition Measurements

Activation Measurements

Biological Processes (93)

Molecular Functions (31)

Ceullar Components (41)

Bioassays (33)

Research

Studies (27)

Market Indicators

Research Demand Index: 11.27

Study Types

4-chlorophenylbiguanide

Cross-References

Synonyms (49)

Research Excerpts

Pharmacokinetics

Dosage Studied

Protein Targets (10)

Inhibition Measurements

Activation Measurements

Biological Processes (93)

Molecular Functions (31)

Ceullar Components (41)

Bioassays (33)

Research

Studies (27)

Market Indicators

Research Demand Index: 11.27

Study Types

Related Drugs (34)

Related Conditions (13)